Business Wire

Earnix Highlights the Potential of Synthetic Data in Specialty Insurance

Share

Earnix, the leading global provider of AI-based SaaS solutions for financial services, today releases a high-level report highlighting the transformative potential of synthetic data to accelerate profitable growth and risk understanding in the context of the unique specialty London insurance market.

The white paper Reshaping London’s Specialty Market -The Impact of Technology and Datahighlights the pivotal role that synthetic data - data that is produced, rather than gathered - will play in the future success of the market.

While synthetic data has been utilized in academia for decades, it's only recently gained traction in mainstream commercial applications. According to Gartner, synthetic data accounted for just 1% of data in 2021 but is projected to grow to 60% by 2024. Technological advancements like generational adversarial networks, transformers, and large language models have significantly increased the speed and volume of synthetic data created.

At the same time, the increasing demand for data in specialty insurance has prompted underwriters and brokers to begin harnessing synthetic data to supplement existing datasets, improving risk assessment efficiency. This is because synthetic data offers solutions to several key challenges in the London Market:

  1. Filling Data Gaps: Specialty insurers can harness synthetic data to access necessary data for product development and testing without compromising security or customer privacy. This has led to a surge in innovative ideas and technology deployment in insurance.
  2. Privacy and Security: Synthetic data maintains confidentiality while enabling critical analysis. In a world of widespread data availability, synthetic data techniques are essential to ensure customer data is not vulnerable to identity theft or fraud.
  3. Analytical Support: Synthetic data supports more accurate modeling, simulation, and testing, particularly in assessing extreme or rare events crucial for the specialty market, such as floods or hurricanes and fraud detection. Insurers can simulate these events to develop robust risk models without waiting for actual occurrences.
  4. Simulations, Stress Testing, and Data Expansion: Generating synthetic data improves the performance of predictive models, enhancing fraud detection and other analytical insights. It allows insurers to simulate and stress-test models in new situations, enabling them to introduce new products or expand into new segments or territories with limited existing data.

Earnix CEO Robin Gilthorpe said:

“The digital transformation of the London market’s complex specialty lines of business has only just begun. While it is a market-wide and fundamental shift in the way specialty insurers and reinsurers do business, it is not a one-size-fits-all solution. However, synthetic data coupled with AI, machine learning, and advanced analytics, holds promise for addressing various challenges in specialty insurance, including data gaps, privacy and security concerns, and fraud detection, among others.

Data plays a crucial role in revenue, profitability, and market share- particularly in this complex market where insight at a granular level can make a significant difference at a macro level. Specialty brokers and insurers know that in this rapidly evolving market, the ability to grow through change is paramount. Our white paper underscores the pivotal role of synthetic data in reshaping the London Market and outlines the next steps available to specialty insurers to harness the unparalleled opportunities for informed decision-making and enhanced operational efficiency.”

Download the report here.

For more information about Earnix, please visit www.earnix.com.

About Earnix

Earnix is the premier provider of mission-critical, cloud-based intelligent solutions across pricing, underwriting, rating, and product personalization. These fully integrated solutions provide ultra-fast ROI and are designed to transform how global insurers and banks are run by unlocking value across all facets of the business. Earnix has been innovating for insurers and banks since 2001, with customers in over 35 countries across six continents and offices in the Americas, Europe, Asia Pacific, and Israel. For more information please visit: earnix.com.

Contact Earnix via LinkedIn, X, and Facebook. Read the Earnix blog.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Krystina Puleo
Global Director of External Communications
press@earnix.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia23.6.2024 04:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized by the accelerated destruction of platelets in blood, resulting in a decreased platelet count and an increase of bleeding that can be debilitating. These data (Abstract #LB 01.1) were presented at the oral Late-Breakthrough Session at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand. Takeda plans to initiate a global Phase 3 trial of mezagitamab in patients with ITP in the second half of FY2024. The TAK-079-1004 trial (NCT04278924) evaluated three different doses of subcutaneous mezagitamab (100mg, 300mg and 600mg) versus placebo, given once weekly for eight weeks in patients with chronic or

PMC Biogenix Announces Expansion and Restructure21.6.2024 23:00:00 CEST | Press release

PMC Biogenix, the leading sustainable producer of specialty fatty amides and high-value biobased products, announces the construction and expansion of its new Armoslip® facility in Gyeongju, South Korea allowing for a production capacity increase of 50%. Construction will begin late 2024 with new supply available by mid-2026. “We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products,” said Debtosh Chakrabarti, President, PMC Group N.A., Inc. Adding, “This project solidifies our commitment as the industry leader, delivering products and solutions to our customers, as well as to the local Gyeongju community. We appreciate the continued support of the Gyeongju, South Korea local government, community, and our customers.” As part of PMC’s ongoing commitment of ensuring long-term sustainability and success of the Biogenix business world-wide, a c

Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials21.6.2024 22:58:00 CEST | Press release

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator. The new tool is designed to simplify and streamline the process by which people with ALS and their caretakers learn about current ALS studies. With the ALS Trial Navigator users can now explore an interactive map to find locations where applicable clinical trials are taking place. They can also receive a customized map based on their preferences and status of their ALS. "ALS Trial Navigator helps people living with ALS, those that might face it in the future, and researchers looking to enroll trials by educating the community and providing information about current studies all around the world," said Dr. Nadia Sethi, ALS TDI's director of community engagement, who oversaw the Navigator's design and creation. Once a person is diagnosed with ALS,

Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting21.6.2024 22:30:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”) held today in the Isle of Man. The ordinary resolutions below were passed by shareholders, with voting results as follows: Ordinary Resolutions For % For Against % Against Abstain % Abstain To receive the Company’s accounts for the financial year ended December 31, 2023 60,456,134 100.00% 0 0.00% 264 0.00% To re-elect John Dowd as a Class I Director of the Company 60,375,930 99.87% 79,177 0.13% 1,291 0.00% To re-elect Govind Friedland as a Class I Director of the Company 59,713,208 98.77% 79,319 0.13% 663,871 1.10% To re-elect Ambassador Mwanaidi Maajar as a Class I Director of the Company 60,314,469 99.77% 81,886 0.14% 60,043 0.10% A total of 60,456,398 or 75.57% of Lifezone Metals Ordinary Shares outstanding were represented at the AGM. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Me

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer21.6.2024 22:00:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2024, and approval by the U.S. Food and Drug Administration (FDA) for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens on November 8, 2023.1,2 “People living with metastatic colorectal cancer face numerous difficulties, stemming both from their illness and the adverse effects of therapies. Given the complex nature of the d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye